Infection and immunity in Down syndrome: a trial of long-term low oral doses of zinc

J Pediatr. 1989 May;114(5):781-7. doi: 10.1016/s0022-3476(89)80136-2.

Abstract

To determine whether orally administered zinc supplements could correct the abnormal humoral and cell-mediated immunity of Down syndrome, we randomly assigned 64 children with Down syndrome, aged 1 to 19 years and living at home, to receive either zinc gluconate or placebo daily for 6-month periods with crossover from one regimen to another. Control subjects were siblings and age-matched, unrelated children. Serum zinc, copper, and measures of immune system competence were tested at 3- or 6-month intervals. Parents kept daily logs of clinical symptoms such as cough and diarrhea and of physician visits. Mean serum zinc concentrations increased to about 150% of baseline during zinc supplementation, but we found no effect on serum levels of copper, immunoglobulins, or complement; on lymphocyte number or subset distribution; or on in vitro response to mitogens. Children with Down syndrome who were receiving zinc had a trend toward fewer days or episodes of cough and fever but no change in other clinical variables. Long-term, low-dose oral zinc supplementation to improve depressed immune response or to decrease infections in children with Down syndrome cannot be recommended.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Child, Preschool
  • Complement System Proteins
  • Copper / blood
  • Down Syndrome / complications
  • Down Syndrome / drug therapy
  • Down Syndrome / immunology*
  • Humans
  • Immunoglobulins
  • Immunologic Deficiency Syndromes / complications
  • Immunologic Deficiency Syndromes / drug therapy*
  • Infant
  • Leukocyte Count
  • Lymphocyte Activation
  • Random Allocation
  • Zinc / blood
  • Zinc / therapeutic use*

Substances

  • Immunoglobulins
  • Copper
  • Complement System Proteins
  • Zinc